Τόμος 32 (2014) – Τεύχος 2 – Άρθρο 5 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 32 (2014) – Issue 2 – Article 5 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Ιωάννα Γκρεκ MSc, PhD
^{Eπίκουρη Καθηγήτρια Αισθητικής και Κοσµητολογίας, ∆ιδάκτωρ Ιατρικής Σχολής Πανεπιστηµίου Αθηνών, Τµήµα Αισθητικής και Κοσµητολογίας, Σχολή Επαγγελµάτων Υγείας και Πρόνοιας, Τεχνολογικό Ίδρυµα Αθηνών, Αθήνα, Ελλάς –}
Ioanna Grech
Department of Aesthetics and Cosmetology, School of Professions of Health and Welfare, Technological Educational Institution of Athens, Egaleo, Athens, Hellas

Γκρεκ Ι.: Επισκόπηση των Νεότερων ∆εδοµένων στην Παθογένεια της Ακµής, Επιθεώρηση Κλιν. Φαρμακολ. Φαρμακοκινητ. 32: 107-112 (2014)
Grech I.: Acne Pathogenesis, Epitheorese Klin. Farmakol. Farmakokinet. 32: 107-112 (2014)

3. Chen W. Thiboutot D., Zouboulis C.C.: Cutaneous androgen metabolism – basic research and clinical perspectives. J. Invest. Dermatol. 119: 992-1007 (2002)

4. Fritsch M. Orfanos C.E., Zouboulis C.C: Sebocytes are the key regulators of androgen homeostasis in human skin. J. Invest. Dermatol. 116: 793-800 (2001)

5. Triboutot D., Jabara S., McAllister J.M.: Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes and an immortalized sebocyte cell line (SEB-1). J. Invest Dermatol. 120: 905-914 (2003)

6. Zouboulis C.C.: Human skin: an independent peripheral endocrine organ. Horm. Res. 54: 230-242 (2000)

7. Zouboulis C.C.: The human skin as a hormone target and an endocrine gland. Hormones 3: 9-26 (2004)

8. Ashcroft G., Mills S.: Androgen receptor mediated inhibition of cutaneous wound healing. J. Clin Invest. 110: 615-624 (2002)

9. Chen W., Yang C.-C., Sheu H.M., Seltmann H., Zouboulis C.C.: Expression of peroxisome proliferator-activated receptorand CCAAT/enhancer binding protein transcription factors in cultured human sebocytes. J. Invest. Dermatol. 121: 441-447 (2003)

10. Shalita M.R.: Clinical aspects of acne. Dermatology 196: 93-94 (1987)

11. Zouboulis C.C., Eady A., Philpott M., Goldsmith L.A., Orfanos C.E., Gunliffe W.C., Rosenfield R.: What is the pathogenesis of acne? Exp. Dermatol.14: 143-152 (2005)

12. Zouboulis C.C.: Human skin: an independent peripheral endocrine organ. Horm. Res. 54: 230-242 (2000)

13. Skurkovich B., Skurkovich S.: Inhibition of IFn – gamma as a method of treatment of various autoimmune diseases, including autoimmune diseases. Ernst Schering Res. Found. Workshop 56: 1-27 (2006)

14. Brydges S., Kaster D.L.: The systemic autoinflammatory diseases: Inborn errors of the innate immune system. Curr. Top. Microbio. Immunol. 305: 127-160 (2006)

15. Webster G.F.: Inflammatory Acne Represents Hypersensitivity to Propionibacterium acnes. Dermatology 166: 80-81 (1998)

16. Webster G.F., Leyden J.J., Tsai C.-C., Baeni P., McArthur W.P.: Polymorphonuclear leukocyte lysosomal enzyme release in response to Propionibacterium acnes in vitro and its enhancement by sera from patients with inflammatory acne. J. Invest. Dermatol. 74: 398-401 (1980)

17. Levell M.J., Cahood M.L., Burke B., Cunliffe W.J.: Acne is not associated with abnormal plasma androgens. Br. J. Dermatol. 120: 649-654 (1989)

18. Sultan C., Oliev V., Aurdan F.: Free and total testosterone in men and women with acne. Acta Derm. Venereol. 66: 301-304 (1986)

19. Webster G.F., Leyden J.J., Norman M.P.: Complement activation in acne vulgaris: Consumption of complement by comedones. Infect. Immun. 26: 186-188 (1979)

20. Puhvel S.M., Warnick M.A., Sterberg T.H.: Levels of antibody to Staphylococcus epidermis in patients with acne vulgaris. Arch. Dermatol. 92: 88-90 (1965)

21. Webster G.F., Indrisano S.P., Leyden J.J.: Antibody titers to Propionibacteriumacnes cell wall carbohydrate in nodulo-cystic acne patients. J. Invest. Dermatol. 84: 496- 500 (1985)

22. Ingham E. Gowland G., Ward R.M., Holland K.T., Cunliffe W.J.: Antibodies to P. acnes and P. acne-sexocellular enzymes in the normal population at various ages and in patients with acne vulgaris. Br. J. Dermatol. 116: 805-812 (1987)

23. Jugeau S., Tenaud I., Knol A.C., Jarousse V., Quereux G., Khammari A., Dreno B.: Induction of toll-like receptors by Propionibacterium acnes. Br. J. Dermatol. 153: 1105- 1113 (2005)

24. Chen K., Huang J., Gong W., Iribarren P., Dunlop N.M., Wang J.M.: Toll like receptors in inflammation, infection and cancer. Int. Immunopharmacol. 7: 1271-1285 (2007)

25. Ermetcan A.T., Ozturk F., Gunduz K.: Toll-like receptors and skin. JEADV 25: 997-1006 (2011)

26. Hari A., Flach T.L., Shi Y., Mydlarski P.R.: Toll-like receptors: role in dermatological disease. Mediators Inflamm. 2010: 437246. Epub 2010 Aug22

27. Valins W., Amini S., Berman B.: The expression of Tolllike receptors in dermatological diseases and the therapeutic effect of current and newer topical Toll-like receptor modulators. J. Clin. Aesthet. Dermatol. 3(9): 20-29 (2010)

28. Kim J., Ochoa M.T., Krutzik S.R., Takeuchi O., Uematsu S., Legaspi A.J., Brightbill H.D., Holland D., Cunliffe W.J., Akira S., Sieling P.A., Godowski P.J., Modlin R.L.: Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J. Immunol. 169: 1535-1541 (2002)

29. Mclnturff J.E., Kim J.: The role of Toll-like receptors in the pathophysiology of acne. Semin. Cutan. Med. Surg. 24: 73-78 (2005)

30. Marcinciewich J., Biedron R., Białecka A., Kasprowicz A., Mak M., Targosz M.: Susceptibility of Propionibacterium acnes and staphylococcus epidermidis to killing by MPOhalide system products. Implications for taurine bromamine as a new candidate for topical therapy in teating acne vulgaris. Arch. Immunol. Ther. Exp. (Warsz) 54: 61-68 (2006)

31. Szabo K., Kemeny L.: Studying the genetic predisposing factors in the pathogenesis of acne vulgaris. Hum. Immunol. 72: 766-773 (2011)